Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of “Hold” from Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been assigned an average recommendation of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.2250.

A number of equities analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd.

Lexicon Pharmaceuticals Price Performance

NASDAQ LXRX opened at $1.16 on Monday. The stock has a market capitalization of $421.54 million, a price-to-earnings ratio of -6.11 and a beta of 0.71. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $1.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63. The business’s fifty day moving average price is $1.31 and its 200-day moving average price is $1.28.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. The company had revenue of $14.18 million for the quarter, compared to the consensus estimate of $5.81 million. Lexicon Pharmaceuticals had a negative return on equity of 52.90% and a negative net margin of 96.77%. On average, equities analysts predict that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Lexicon Pharmaceuticals by 7.6% during the 3rd quarter. Vanguard Group Inc. now owns 9,521,874 shares of the biopharmaceutical company’s stock valued at $12,855,000 after acquiring an additional 670,838 shares during the period. Millennium Management LLC lifted its holdings in Lexicon Pharmaceuticals by 133.1% during the third quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock valued at $5,171,000 after purchasing an additional 2,187,396 shares in the last quarter. UBS Group AG boosted its position in shares of Lexicon Pharmaceuticals by 752.1% in the fourth quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock worth $3,458,000 after purchasing an additional 2,654,315 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in shares of Lexicon Pharmaceuticals in the third quarter worth $3,240,000. Finally, AQR Capital Management LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at $541,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.